上海市医学会检验医学专科分会生化组副组长
Deputy Leader of Biochemistry Group, Shanghai Medicine Association of Laboratory Medicine
上海市级医院检验专科联盟秘书
Secretary of Shanghai Municipal Hospital Laboratory Specialty Alliance
上海市康复医学会检验与健康专委会委员兼秘书
Member and Secretary of the Laboratory and Health Special Committee, Shanghai Rehabilitation Medicine Association
上海市中西医结合学会医学检验专委会委员
Member of the Medical Laboratory Special Committee, Shanghai Chinese and Western Medicine Association
中国抗癌协会肿瘤标志物专委会委员
Member of the Tumor Markers Committee of the Chinese Anti-Cancer Association
白求恩精神研究会检验医学分会常务副会长
Executive Vice President of the Laboratory Medicine Branch, Bethune Spirit Research Association
《Clinica Chimica Acta》杂志编委
Editorial Board Member of Clinica Chimica Acta Magazine
上海市政府采购评审专家
Evaluation Expert of Shanghai Municipal Government Procurement
以第一负责人主持国家级、省部级、局级等课题10余项；以第一作者或通讯作者发表论文40余篇，其中SCI论文20余篇，单篇最高IF为33.9分，10分以上6篇，包括Molecular Cancer、Cancer Research、Theranostics等国际著名期刊；主编/参编专著6本；申请发明专利10项，其中7项已授权；荣获上海市医师协会检验医师分会优秀检验技师称号、上海市同济医院“十佳管理人员”称号、上海市同济医院“十佳” 科研人员称号，入选上海市同济医院“宝隆访学计划”，以主要完成人员获得上海康复学会科技奖二等奖一项。
Professor Zujun Sun have presided over more than ten national, provincial, and bureau level research projects as the first person in charge. He published over 40 papers as the first author or corresponding author, including more than 20 SCI papers, with a maximum IF score of 33.9 for a single paper, and 6 papers with scores above 10, such as Molecular Cancer, Cancer Research, Theranostics, etc. Editor in chief/co-editor of 6 monographs. Applied for 10 invention patents, of which 7 have been authorized. Awarded the title of Excellent Laboratory Technician by the Inspection Physician Branch of the Shanghai Medical Association, the title of "Top Ten Management Personnel" by Tongji Hospital in Shanghai, and the title of "Top Ten Scientific Research Personnel" by Tongji Hospital in Shanghai. Also selected for the "Baolong Visiting Study Plan" by Tongji Hospital in Shanghai, and awarded the second prize of the Shanghai Rehabilitation Society Science and Technology Award for the main completion personnel.
【立项课题（主持课题）】
1. 2025.6-2028.5 上海市申康医院发展中心诊疗技术推广及优化管理项目（12025124SHDC），30万元；
2. 2024.10-2027.9 上海市同济医院专利孵化项目，3万元；
3. 2020.1-2023.12 国家自然基金面上项目(81974314) ，55万元；
4.2019.6-2022.5 上海市同济医院临床研究培育重点项目[ITJ(ZD)1905]，25万元；
5.2019.5-2022.4 上海市自然科学基金(19ZR1448800)， 20万元；
6.2019.4-2022.3 上海市科委医学引导类项目(19411964800)， 20万元；
7.2018.10-2019.9 上海市同济医院国家自然科学基金培育项目(GJPY1804) ，5万元；
8.2018.1-2020.12 上海市科委智慧即时检测示范应用研究(17DZ1930301) ，3万元；
9.2011.1-2013.12 国家自然科学基金青年项目(81001205)，20 万元；
10.2010.10-2012.9 上海交通大学医学院附属第九人民医院培育项目， 2 万元。
【代表性论著（第一/通讯作者）】
1. TERC stimulates fatty acid metabolism to promote bladder cancer progression. Cancer Res 2025; 85:3689–705.
2. The clinical value of rapidly detecting urinary exosomal lncRNA RMRP in bladder cancer with an RT-RAA-CRISPR/Cas12a method. Clinica Chimica Acta. 2024,562,119855.
3. Exosomal long non-coding ribonucleic acid ribonuclease component of mitochondrial ribonucleic acid processing endoribonuclease Is defined as a potential non-invasive diagnostic biomarker for bladder cancer and facilitates tumorigenesis via the miR-206/G6PD axis. Cancers. 2023, 15,5305.
4. A novel bivalentanti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity againstc-MET/PD-L1-positive colorectal cancer. Investigational New Drugs. 2023,41(5):737-750.
5. Identification of CD147-positive extracellular vesicles as novel non-invasive biomarkers for thediagnosis and prognosis of colorectal cancer. Clinica Chimica Acta. 2023,548:117510.
6. Proteomics-basedidentification of candidate exosomal glycoprotein biomarkers andtheir value for diagnosing colorectal cancer. Frontiers in Oncology. 2021,11:725211.
7. Exosomal circPACRGL promotes progressionof colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis. Mol Cancer.2020; 19(1):117.
8. Exosomal KRAS mutation promotes the formation oftumor-associated neutrophil extracellular traps and causes deterioration ofcolorectal cancer by inducing IL-8 expression. Cell Communication andSignaling. 2020; 18:52.
9. Anomogram from the SEER database for predicting the prognosis of patients withnon-small cell lung cancer. International Journal of Biochemistry andCell Biology. 2020,127:105825.
10. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape ofovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.Journal of Experimental & Clinical Cancer Research. 2019; 38: 1-15.
11. Bronchoalveolar lavage fluid-derived exosomes: a novel role contributing tolung cancer growth. Front Oncol. 2019; 197:1-10.
12. Myeloid cell-derived LL-37promotes lung cancergrowth by activating Wnt/β-catenin signaling. Theranostics. 2019;9(8): 2209-2223.
13. A novel humanized anti-PD-1 monoclonalantibody potentiates therapy in oral squamous cell carcinoma. Ivest New Drug. 2019;37(5): 799-809.
14. The value of red blood cell distribution width in diagnosis of patients with colorectal cancer. Clinica Chimica Acta. 2018;479:98-102.
15. A deficiency in cathelicidin reduces lung tumorgrowth in NNK/NTHi-induced A/J mice. Am J Cancer Res. 2018; 8(7):1190-1199.
16. Role oftoll-like receptor 4 on the immune escape of human oral squamous cell carcinomaand resistance of cisplatin-induced apoptosis. Mol Cancer. 2012; 1(33):1-12.
